Cargando…

A New Therapeutic Candidate for Cardiovascular Diseases: Berberine

Cardiovascular diseases (CVD) are the leading cause of death in the world. However, due to the limited effectiveness and potential adverse effects of current treatments, the long-term prognosis of CVD patients is still discouraging. In recent years, several studies have found that berberine (BBR) ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Yun, Xin, Qiqi, Lu, Jinjin, Miao, Yu, Lin, Qian, Cong, Weihong, Chen, Keji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010184/
https://www.ncbi.nlm.nih.gov/pubmed/33815112
http://dx.doi.org/10.3389/fphar.2021.631100
_version_ 1783673010725584896
author Cai, Yun
Xin, Qiqi
Lu, Jinjin
Miao, Yu
Lin, Qian
Cong, Weihong
Chen, Keji
author_facet Cai, Yun
Xin, Qiqi
Lu, Jinjin
Miao, Yu
Lin, Qian
Cong, Weihong
Chen, Keji
author_sort Cai, Yun
collection PubMed
description Cardiovascular diseases (CVD) are the leading cause of death in the world. However, due to the limited effectiveness and potential adverse effects of current treatments, the long-term prognosis of CVD patients is still discouraging. In recent years, several studies have found that berberine (BBR) has broad application prospects in the prevention and treatment of CVD. Due to its effectiveness and safety for gastroenteritis and diarrhea caused by bacterial infections, BBR has been widely used in China and other Asian countries since the middle of the last century. The development of pharmacology also provides evidence for the multi-targets of BBR in treating CVD. Researches on CVD, such as arrhythmia, atherosclerosis, dyslipidemia, hypertension, ischemic heart disease, myocarditis and cardiomyopathy, heart failure, etc., revealed the cardiovascular protective mechanisms of BBR. This review systematically summarizes the pharmacological research progress of BBR in the treatment of CVD in recent years, confirming that BBR is a promising therapeutic option for CVD.
format Online
Article
Text
id pubmed-8010184
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80101842021-04-01 A New Therapeutic Candidate for Cardiovascular Diseases: Berberine Cai, Yun Xin, Qiqi Lu, Jinjin Miao, Yu Lin, Qian Cong, Weihong Chen, Keji Front Pharmacol Pharmacology Cardiovascular diseases (CVD) are the leading cause of death in the world. However, due to the limited effectiveness and potential adverse effects of current treatments, the long-term prognosis of CVD patients is still discouraging. In recent years, several studies have found that berberine (BBR) has broad application prospects in the prevention and treatment of CVD. Due to its effectiveness and safety for gastroenteritis and diarrhea caused by bacterial infections, BBR has been widely used in China and other Asian countries since the middle of the last century. The development of pharmacology also provides evidence for the multi-targets of BBR in treating CVD. Researches on CVD, such as arrhythmia, atherosclerosis, dyslipidemia, hypertension, ischemic heart disease, myocarditis and cardiomyopathy, heart failure, etc., revealed the cardiovascular protective mechanisms of BBR. This review systematically summarizes the pharmacological research progress of BBR in the treatment of CVD in recent years, confirming that BBR is a promising therapeutic option for CVD. Frontiers Media S.A. 2021-03-17 /pmc/articles/PMC8010184/ /pubmed/33815112 http://dx.doi.org/10.3389/fphar.2021.631100 Text en Copyright © 2021 Cai, Xin, Lu, Miao, Lin, Cong and Chen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cai, Yun
Xin, Qiqi
Lu, Jinjin
Miao, Yu
Lin, Qian
Cong, Weihong
Chen, Keji
A New Therapeutic Candidate for Cardiovascular Diseases: Berberine
title A New Therapeutic Candidate for Cardiovascular Diseases: Berberine
title_full A New Therapeutic Candidate for Cardiovascular Diseases: Berberine
title_fullStr A New Therapeutic Candidate for Cardiovascular Diseases: Berberine
title_full_unstemmed A New Therapeutic Candidate for Cardiovascular Diseases: Berberine
title_short A New Therapeutic Candidate for Cardiovascular Diseases: Berberine
title_sort new therapeutic candidate for cardiovascular diseases: berberine
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010184/
https://www.ncbi.nlm.nih.gov/pubmed/33815112
http://dx.doi.org/10.3389/fphar.2021.631100
work_keys_str_mv AT caiyun anewtherapeuticcandidateforcardiovasculardiseasesberberine
AT xinqiqi anewtherapeuticcandidateforcardiovasculardiseasesberberine
AT lujinjin anewtherapeuticcandidateforcardiovasculardiseasesberberine
AT miaoyu anewtherapeuticcandidateforcardiovasculardiseasesberberine
AT linqian anewtherapeuticcandidateforcardiovasculardiseasesberberine
AT congweihong anewtherapeuticcandidateforcardiovasculardiseasesberberine
AT chenkeji anewtherapeuticcandidateforcardiovasculardiseasesberberine
AT caiyun newtherapeuticcandidateforcardiovasculardiseasesberberine
AT xinqiqi newtherapeuticcandidateforcardiovasculardiseasesberberine
AT lujinjin newtherapeuticcandidateforcardiovasculardiseasesberberine
AT miaoyu newtherapeuticcandidateforcardiovasculardiseasesberberine
AT linqian newtherapeuticcandidateforcardiovasculardiseasesberberine
AT congweihong newtherapeuticcandidateforcardiovasculardiseasesberberine
AT chenkeji newtherapeuticcandidateforcardiovasculardiseasesberberine